生物可降解支架的临床应用进展

被引：8

作者：

高立建

陈纪林

机构：

[1] 中国医学科学院北京协和医学院国家心血管病中心阜外医院冠心病诊治中心

来源：

中国循环杂志 | 2017年 / 32卷 / 03期

关键词：

评论; 支架; 血管成形术,经腔,经皮冠状动脉;

D O I：

暂无

中图分类号：

R541.4 [冠状动脉（粥样）硬化性心脏病（冠心病）];

学科分类号：

100201 [内科学];

摘要：

在过去的40年经皮冠状动脉介入治疗(PCI)策略在不断进展,新一代药物洗脱支架(DES)明显降低了支架内再狭窄,提高了临床疗效。但金属的永久存留、再狭窄、血栓和对患者心理上的影响,限制了其在部分病情复杂患者中的应用。生物可降解支架(BRS)是支架技术的一大进步,可以完全吸收恢复血管自身弹性、应变力、生理剪切力,是冠心病介入治疗领域的第四次革命,有可能解决上述问题。

引用

页码：215 / 216

页数：2

共 5 条

[1]

A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan [J].

Kimura, Takeshi ;

Kozuma, Ken ;

Tanabe, Kengo ;

Nakamura, Sunao ;

Yamane, Masahisa ;

Muramatsu, Toshiya ;

Saito, Shigeru ;

Yajima, Junji ;

Hagiwara, Nobuhisa ;

Mitsudo, Kazuaki ;

Popma, Jeffrey J. ;

Serruys, Patrick W. ;

Onuma, Yoshinobu ;

Ying, Shihwa ;

Cao, Sherry ;

Staehr, Peter ;

Cheong, Wai-Fung ;

Kusano, Hajime ;

Stone, Gregg W. .

EUROPEAN HEART JOURNAL, 2015, 36 (47) :3332-3342

[2]

Clinical Comparison With Short-Term Follow-Up of Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Stent in Primary Percutaneous Coronary Interventions[J] Bernardo Cortese;Alfonso Ielasi;Enrico Romagnoli;Attilio Varricchio;Andrea Cuculo;Bruno Loi;Francesco Pisano;Donatella Corrado;Marco Sesana;Luigi La Vecchia;Francesco Summaria;Maurizio Tespili;Pedro Silva Orrego;Gianni Tognoni;Giuseppe Steffenino The American Journal of Cardiology 2015,

[3]

A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial[J] Patrick W Serruys;Bernard Chevalier;Dariusz Dudek;Angel Cequier;Didier Carrié;Andres Iniguez;Marcello Dominici;René J van der Schaaf;Michael Haude;Luc Wasungu;Susan Veldhof;Lei Peng;Peter Staehr;Maik J Grundeken;

[4]

Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease[J] Runlin Gao;Yuejin Yang;Yaling Han;Yong Huo;Jiyan Chen;Bo Yu;Xi Su;Lang Li;Hai-Chien Kuo;Shih-Wa Ying;Wai-Fung Cheong;Yunlong Zhang;Xiaolu Su;Bo Xu;Jeffery J. Popma;Gregg W. Stone Journal of the American College of Cardiology 2015,

[5]

Decade of Histological Follow-Up for a Fully Biodegradable Poly-l-lactic Acid Coronary Stent (Igaki-Tamai Stent) in Humans: Are Bioresorbable Scaffolds the Answer?[J] Soji Nishio;Shinsaku Takeda;Kunihiko Kosuga;Masaharu Okada;Eisho Kyo;Takafumi Tsuji;Eiji Takeuchi;Tsuyoshi Terashima;Yasutaka Inuzuka;Tatsuhiko Hata;Yuzo Takeuchi;Takeshi Harita;Junya Seki;Shigeru Ikeguchi Circulation 2014,

← 1 →